Insight Molecular Diagnostics (IMDX)

• Market cap: $93.6M
• 1 day: -4.11%
• 5 days: 4.47%
• 1 month: 26.25%
• 3 months: -10.66%
• 6 months: -1.8%
• Year to date: 40.34%
• 1 year: 3.81%
• 5 years: -87.8%
• 10 years: -98.18%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.

Employees: 49

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

0% more funds holding

Funds holding: 30 [Q1] → 30 (+0) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

1% less capital invested

Capital invested by funds: $49.2M [Q1] → $48.9M (-$322K) [Q2]

2.88% less ownership

Funds ownership: 56.27% [Q1] → 53.38% (-2.88%) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4.25
• Avg. target: $4.25
• High target: $4.25

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Needham Mike Matson

$4.25

Buy Reiterated

18 Aug 2025